By Disease TypeUlcerative Proctitis · Left-Sided Colitis · Pancolitis · and Fulminant Colitis
By Disease SeverityMild Ulcerative Colitis · Moderate Ulcerative Colitis · and Severe Ulcerative Colitis
By Route of AdministrationOral · Parenteral · and Rectal
By Age GroupAdults · Pediatrics · and Geriatric
By GenderMale and Female
By Distribution ChannelHospital Pharmacies · Retail Pharmacies · and Online Pharmacies
By End UserHospitals and Clinics · Infusion Centers · Specialty Gastroenterology Clinics · Ambulatory Surgical Centers (ASCs) · Research and Diagnostic Laboratories · and Home Healthcare Settings
By GeographyNorth America · Europe · Asia Pacific · Latin America · Middle East · and Africa
Published In17 Mar 2026
Report CodeCMI8592
Pages250+
FormatsExcel and PDF
Base Year2025
Estimated Year2026
Historical Range2020 - 2024
Forecast Period2026-2033
Market Segmentation
Molecule Type Insights (Revenue, USD Bn, 2021 - 2033)
Biologics
Small Molecules
Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
Aminosalicylates
Mesalamine (Asacol HD, Lialda)
Olsalazin
Corticosteroids
Budesonide (Uceris)
Prednisone
Anti-TNF Biologics
Infliximab (Remicade)
Adalimumab (Humira)
Integrin Receptor Antagonists
Vedolizumab (Entyvio)
Janus Kinase (JAK) Inhibitors
Tofacitinib (Xeljanz)
Upadacitinib (Rinvoq)
Interleukin (IL)-12/23 Inhibitors
Ustekinumab (Stelara)
Risankizumab (Skyrizi)
Sphingosine 1-Phosphate (S1P) Receptor Modulators
Ozanimod (Zeposia)
Etrasimod (Velsipity)
Immunosuppressants
Azathioprine
6-Mercaptopurine
Others
Disease Type Insights (Revenue, USD Bn, 2021 - 2033)